Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fibrobiologics Inc (FBLG)

Fibrobiologics Inc (FBLG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,375
  • Shares Outstanding, K 3,513
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,650 K
  • EBIT $ -17 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.25
  • Number of Estimates 2
  • High Estimate $-1.20
  • Low Estimate $-1.31
  • Prior Year $-2.80
  • Growth Rate Est. (year over year) +55.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +48.54%
on 04/01/26
5.5980 -72.67%
on 03/18/26
-3.9940 (-72.30%)
since 03/17/26
3-Month
1.0300 +48.54%
on 04/01/26
9.5980 -84.06%
on 03/03/26
-5.1680 (-77.16%)
since 01/16/26
52-Week
1.0300 +48.54%
on 04/01/26
30.6000 -95.00%
on 04/22/25
-22.2700 (-93.57%)
since 04/17/25

Most Recent Stories

More News
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

HOUSTON, April 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending...

FBLG : 1.5300 (+0.66%)
FibroBiologics Announces Closing of $3 Million Public Offering

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending...

FBLG : 1.5300 (+0.66%)
FibroBiologics Announces Pricing of $3 Million Public Offering

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending...

FBLG : 1.5300 (+0.66%)
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...

FBLG : 1.5300 (+0.66%)
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...

FBLG : 1.5300 (+0.66%)
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...

FBLG : 1.5300 (+0.66%)
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...

FBLG : 1.5300 (+0.66%)
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending...

FBLG : 1.5300 (+0.66%)
FibroBiologics to Present at the BIO Investment & Growth Summit

HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the...

FBLG : 1.5300 (+0.66%)
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026 Improved balance sheet through multiple direct offerings; completed...

FBLG : 1.5300 (+0.66%)

Business Summary

FibroBiologics Inc. is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics Inc. is based in HOUSTON.

See More

Key Turning Points

3rd Resistance Point 2.1367
2nd Resistance Point 1.9833
1st Resistance Point 1.7567
Last Price 1.5300
1st Support Level 1.3767
2nd Support Level 1.2233
3rd Support Level 0.9967

See More

52-Week High 30.6000
Fibonacci 61.8% 19.3043
Fibonacci 50% 15.8150
Fibonacci 38.2% 12.3257
Last Price 1.5300
52-Week Low 1.0300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.